Latest news with #EmiratiGenomeProgram
Arab News
31-03-2025
- Business
- Arab News
Cleveland Clinic and G42 to advance healthcare through artificial intelligence
Cleveland Clinic and G42, a global leader in artificial intelligence, are collaborating to drive AI-powered advancements in healthcare. As part of this initiative, the organizations will form a joint task force to evaluate, prioritize and accelerate potential projects and collaborative opportunities aimed at advancing AI adoption in healthcare. G42 is a technology group headquartered in Abu Dhabi, United Arab Emirates, known for its advanced innovation in artificial intelligence, digital infrastructure, and big data analytics solutions across a wide range of industries. Its healthcare portfolio company spanning 480 clinics in 26 countries, M42, leads some of the most groundbreaking health advancements in the industry, such as the Emirati Genome Program, the world's largest genomics initiative, and Malaffi, Abu Dhabi's Health Information Exchange. Cleveland Clinic is a global health system that includes 23 hospitals, 280 outpatient facilities, and American locations in northeast Ohio, Florida and Nevada and international locations in Toronto, Abu Dhabi, and London. In 2024, Cleveland Clinic provided 15.7 million outpatient encounters, 333,000 hospital admissions and observations, and 320,000 surgeries and procedures worldwide. 'Cleveland Clinic is committed to finding opportunities that improve patient safety, patient experience, patient outcomes and access,' said Cleveland Clinic CEO and president Tom Mihaljevic, MD, holder of the Morton L. Mandel CEO Chair. 'Artificial intelligence offers a tremendous opportunity to continue to advance and fulfill our mission of caring for life, researching for health and educating those who serve.' As part of the collaboration, G42 and Cleveland Clinic will explore and implement transformative AI-driven healthcare initiatives that have the potential to redefine patient care, enhance medical innovation, and drive operational efficiencies. These efforts will benefit not only the UAE and the wider region but extend globally, shaping the future of healthcare through intelligent, data-driven solutions. 'AI's potential to transform the healthcare industry remains largely untapped,' said Peng Xiao, Group CEO of G42. 'From deciphering the source code of life — our genome — to optimizing efficiencies across the entire patient journey, AI is paving the way for a future where care is not only more precise but also deeply personalized and preventative. We look forward to embarking on this journey alongside Cleveland Clinic and other global partners, harnessing AI to unlock new frontiers in medicine, empower clinicians with unprecedented insights, and ultimately, reshape the way humanity experiences health and longevity.' For the seventh consecutive year, Cleveland Clinic is the No. 2 hospital in the world, according to Newsweek's World's Best Hospitals 2025 list. The global healthcare system has pioneered many medical breakthroughs, including coronary artery bypass surgery, deep brain stimulation surgery to restore function after a stroke, and the first face transplant in the United States. In 2023, the IBM Quantum System One was installed at Cleveland Clinic; it is the first quantum computer in the world to be dedicated to healthcare research with an aim to help Cleveland Clinic accelerate biomedical discoveries.
Arabian Business
31-03-2025
- Business
- Arabian Business
Cleveland Clinic, G42 partner to advance AI in healthcare, driving innovation and patient care
Cleveland Clinic and G42, a global leader in artificial intelligence (AI), said they will collaborate to drive AI-powered advancements in healthcare. As part of this initiative, the two will form a joint task force to evaluate, prioritize and accelerate potential projects and collaborative opportunities aimed at advancing AI adoption in healthcare. Cleveland Clinic's AI-driven future The collaboration envisages G42 and Cleveland Clinic exploring and implementing transformative AI-driven healthcare initiatives that have the potential to redefine patient care, enhance medical innovation, and drive operational efficiencies. The efforts are expected to benefit not only the UAE and the wider region, but extend globally, shaping the future of healthcare through intelligent, data-driven solutions. 'AI's potential to transform the healthcare industry remains largely untapped,' said Peng Xiao, Group CEO of G42. 'From deciphering the source code of life – our genome – to optimising efficiencies across the entire patient journey, AI is paving the way for a future where care is not only more precise but also deeply personalised and preventative,' he said. Xiao said the company looks forward to embarking on this journey alongside Cleveland Clinic and other global partners, harnessing AI to unlock new frontiers in medicine, empower clinicians with unprecedented insights, and ultimately, reshape the way humanity experiences health and longevity. Tom Mihaljevic, CEO and President of Cleveland Clinic, said the healthcare company is committed to finding opportunities that improve patient safety, patient experience, patient outcomes and access. 'Artificial intelligence offers a tremendous opportunity to continue to advance and fulfill our mission of caring for life, researching for health and educating those who serve,' said Mihaljevic, who is also the Morton L. Mandel CEO Chair. G42, a technology group headquartered in Abu Dhabi, is known for its advanced innovation in AI, digital infrastructure, and big data analytics solutions across a wide range of industries. Its healthcare portfolio company spanning 480 clinics in 26 countries, M42, leads some of the most groundbreaking health advancements in the industry, such as the Emirati Genome Program, the world's largest genomics initiative, and Malaffi, Abu Dhabi's Health Information Exchange. Cleveland Clinic, which has a unit in Abu Dhabi, is a global health system that includes 23 hospitals and 280 outpatient facilities.
Zawya
26-03-2025
- Business
- Zawya
Cleveland Clinic and G42 to advance healthcare through artificial intelligence
ABU DHABI, United Arab Emirates: Cleveland Clinic and G42, a global leader in artificial intelligence (AI), are collaborating to drive AI-powered advancements in healthcare. As part of this initiative, the organizations will form a joint task force to evaluate, prioritize and accelerate potential projects and collaborative opportunities aimed at advancing AI adoption in healthcare. G42 is a technology group headquartered in Abu Dhabi, United Arab Emirates (UAE), known for its advanced innovation in artificial intelligence, digital infrastructure, and big data analytics solutions across a wide range of industries. Its healthcare portfolio company spanning 480 clinics in 26 countries, M42, leads some of the most groundbreaking health advancements in the industry, such as the Emirati Genome Program, the world's largest genomics initiative, and Malaffi, Abu Dhabi's Health Information Exchange. Cleveland Clinic is a global health system that includes 23 hospitals, 280 outpatient facilities, and American locations in northeast Ohio, Florida and Nevada and international locations in Toronto, Abu Dhabi, and London. In 2024, Cleveland Clinic provided 15.7 million outpatient encounters, 333,000 hospital admissions and observations, and 320,000 surgeries and procedures worldwide. 'Cleveland Clinic is committed to finding opportunities that improve patient safety, patient experience, patient outcomes and access,' said Cleveland Clinic CEO and President Tom Mihaljevic, M.D., holder of the Morton L. Mandel CEO Chair. 'Artificial intelligence offers a tremendous opportunity to continue to advance and fulfill our mission of caring for life, researching for health and educating those who serve.' As part of the collaboration, G42 and Cleveland Clinic will explore and implement transformative AI-driven healthcare initiatives that have the potential to redefine patient care, enhance medical innovation, and drive operational efficiencies. These efforts will benefit not only the UAE and the wider region but extend globally, shaping the future of healthcare through intelligent, data-driven solutions. 'AI's potential to transform the healthcare industry remains largely untapped,' said Peng Xiao, Group CEO of G42. 'From deciphering the source code of life - our genome - to optimizing efficiencies across the entire patient journey, AI is paving the way for a future where care is not only more precise but also deeply personalized and preventative. We look forward to embarking on this journey alongside Cleveland Clinic and other global partners, harnessing AI to unlock new frontiers in medicine, empower clinicians with unprecedented insights, and ultimately, reshape the way humanity experiences health and longevity." For the seventh consecutive year, Cleveland Clinic is the No. 2 hospital in the world, according to Newsweek's World's Best Hospitals 2025 list. The global healthcare system has pioneered many medical breakthroughs, including coronary artery bypass surgery, deep brain stimulation surgery to restore function after a stroke, and the first face transplant in the United States. In 2023, the IBM Quantum System One was installed at Cleveland Clinic; it is the first quantum computer in the world to be dedicated to healthcare research with an aim to help Cleveland Clinic accelerate biomedical discoveries. About Cleveland Clinic Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic's 82,600 employees worldwide are more than 5,786 salaried physicians and researchers, and 20,700 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,728-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 280 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2024, there were 15.7 million outpatient encounters, 333,000 hospital admissions and observations, and 320,000 surgeries and procedures throughout Cleveland Clinic's health system. Patients came for treatment from every state and 112 countries. Visit us at Follow us at News and resources are available at About G42 G42 is a technology holding group, a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating worldwide, G42 champions AI as a powerful force for good across industries. From molecular biology to space exploration and everything in between, G42 realizes exponential possibilities, today.
Al Etihad
14-03-2025
- Health
- Al Etihad
Khaled bin Mohamed bin Zayed chairs Emirates Genome Council meeting
14 Mar 2025 21:11 ABU DHABI (ALETIHAD)His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, has chaired the meeting of the Emirates Genome the meeting, the board discussed plans to prioritise precision medicine initiatives that leverage genomic data to actively enhance public health outcomes for the UAE population, advance the efficiency of the UAE healthcare system, drive economic and industry growth, and further establish the UAE as a global hub for precision medicine through the advancement of R& Highness Sheikh Khaled bin Mohamed bin Zayed reaffirmed that the UAE leadership is committed to further advancing the health and wellbeing of the community and emphasised the importance of research and development in the fields of longevity, precision medicine and preventative care in enhancing public Highness praised efforts to further advance the UAE as a leader at the forefront of global genomic research and application that prioritises health outcomes and enhances quality of life. New population screening programmes During the meeting, His Highness endorsed new population screening programmes that expand the utilisation of genomic data and accelerate genome-driven personalised healthcare in the UAE. The programmes include newborn genetic screenings, enhanced screenings of adult participants in the Emirati Genome Program, provision of personalised fertility programmes, and cardiovascular genetic newborn genetic screening programme will assess genetic conditions with available treatments and early intervention options for infants, assessing 733 genes to test for more than 800 disease screenings, for adults participating in the Emirati Genome Program, aim to further identify actionable and relevant conditions for UAE Nationals, by assessing 94 genes linked to more than 50 genetic personalised fertility programme assesses 186 genes linked to more than 130 genetic conditions, to provide personalised medicine recommendations and treatments for screenings will provide genetic diagnosis and treatment, as well as early prevention, for cardiovascular related conditions through the assessment of more than 800 genes linked to more than 100 genetic conditions. T2T Emirati Reference Genome study His Highness was briefed on the completion of the landmark Telomere-to-Telomere (T2T) Emirati Reference Genome study aimed at advancing precision medicine for communities in the UAE. The study, by the Department of Health – Abu Dhabi, in collaboration with Khalifa University and M42, bridges critical gaps in genomic data and provides a vital resource that enhances the ability to compare with other reference genomes, supporting the advancement of disease research, pharmacogenomics and the development of Emirati-specific targeted therapies. Premarital Genetic Screening Programme updateHis Highness was also briefed on the progress of the Premarital Genetic Screening Programme, which was nationally implemented from January 1, 2025 by the Ministry of Health and Prevention, in collaboration with the Department of Health – Abu Dhabi, Emirates Heath Services, Dubai Health Authority, and strategic partners. To date, it has supported 2,428 couples, finding more than 92 per cent genetically compatible through comprehensive genetic screening of 570 genes linked to more than 840 genetic disorders. Couples who required additional support were provided personalised genetic counselling to assess and diagnose risk factors and offer potential solutions to support family planning programme aims to safeguard community members from hereditary diseases and empower couples to utilise genetic data to make informed decisions in family planning, preserving the health and wellbeing of community members and ensuring a healthier future for generations to come. Emirati Genome Program progressHis Highness was also updated on the progress of the Emirati Genome Program, which has collected more than 700,000 genetic samples from citizens across the nation, marking significant progress towards the overall target of 1 million. In addition, the Emirati Genome Program has completed the collection of 100,000 samples from participants from different nationalities for a new initiative that leverages the UAE's advanced genomic capabilities. The project, in collaboration with M42, helps reduce gaps in genomic data globally by providing insights into genetic mutations affecting over 2.5 billion people across different ethnicities, with the aim to drive further collaboration on precision medicine research and Emirati Genome Program is a key project under the National Genome Strategy and will support the transformation of healthcare services in the UAE by providing high-quality genetic data that enables researchers, physicians and scientists to identify the causes of genetic diseases, understand the type of genetic mutations, anticipate susceptibility to some diseases, and develop effective personalised healthcare plans. The meeting was attended by His Excellency Mohammad Al Gergawi, UAE Minister of Cabinet Affairs; Her Excellency Sarah bint Yousef Al Amiri, UAE Minister of Education; His Excellency Omar bin Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications; His Excellency Mansour Ibrahim Al Mansouri, Chairman of the Department of Health – Abu Dhabi; His Excellency Saif Saeed Ghobash, Secretary General of the Abu Dhabi Executive Council; His Excellency Dr Amer Ahmed Al-Sharif, the CEO of Dubai Health and President of Mohammed Bin Rashid University of Medicine and Health Sciences; and His Excellency Dr Yousif Mohammed Al-Serkal, Director-General of Emirates Health Services.
Zawya
29-01-2025
- Health
- Zawya
M42 signals genomics expansion with strategic partnership with Uzbekistan's Ministry of Health on the Uzbek Genome Program
Abu Dhabi: In a sign of its ambition to expand its foothold in genomics and grow its contribution to global genomics diversity, M42 and Uzbekistan's Ministry of Health have signed a Memorandum of Understanding ('MoU') to collaborate and explore opportunities for strategic partnerships on the Uzbek Genome Program. Coinciding with an official visit by the President of Uzbekistan Shavkat Mirziyoyev to the UAE at the invitation of UAE president Sheikh Mohammed bin Zayed Al Nahyan, a signing ceremony took place at Rotana Beach, Abu Dhabi between Farhkodjon Tashpulatov, Uzbekistan's Deputy Minister of Health, Shokhrukh Gulamov, Uzbekistan's Deputy Minister of Investments, and Dr Fahed Al Marzooqi, Deputy Chief Operating Officer at M42, in the presence of H.E. Suhail Mohamed Al Mazrouei, the UAE's Minister of Energy, and H.E. Laziz Kudratov, Uzbekistan's Minister of Investments, Industry and Trade. Both M42 and the Uzbekistan's Ministry of Health committed to grow their strategic partnership on genomics to support the healthcare ambitions of the country. The partnership aims to collaborate in the fields of genomics, next-generation prevention, novel screening, and diagnostics development in the Republic of Uzbekistan, with projects including but not limited to: Developing in-country genomic/omics capabilities to enable an Uzbek Genome Program and a new level of understanding of Uzbek genetic diversity and diseases; Designing, developing and manufacturing locally and regionally relevant, scalable screening and diagnostic tools, to transform early disease identification and prevention; Supporting the deployment of genetically inherited disease prevention programs including pre-marital, newborn and non-invasive prenatal testing, but also expanding to other diseases such as cancer and cardiovascular exercises; Supporting the research, development, manufacturing and export of novel screening and diagnostics 'made in Uzbekistan'; and knowledge transfer, training, workforce upskilling Through its partnerships with the UAE healthcare authorities and institutions on the Emirati Genome Program, M42's capabilities in building a comprehensive genetic database specific to the local population has allowed healthcare professionals to identify and address the unique genetic factors contributing to disease risk in the UAE. Building on such expertise, the partnership agreement between M42 and Uzbekistan's Ministry of Health will explore a build, operate and transfer model for genomics to benefit the Uzbek people by tackling disease, advancing early detection, and supporting the shift of the country's healthcare sector to prevention. Commenting on the agreement, 'Genomic research offers unique opportunities to understand the genetic characteristics of the Uzbek population, enabling the creation of targeted programs for early detection and prevention. We are proud to be part of a global initiative in genomic research aimed at improving population health and reducing the burden of chronic diseases,' said Farhkodjon Tashpulatov, Uzbekistan's Deputy Minister of Health. 'Through this strategic partnership with M42, we are not only advancing the potential of our national healthcare system but also contributing to global efforts to explore genetic diversity. Special attention will be given to training our specialists and integrating advanced technologies, positioning Uzbekistan as a leader in genomics in Central Asia. The signing of this memorandum marks a significant milestone for our country in the field of healthcare. The development and implementation of the program will lay the foundation for new standards in prevention, diagnosis, and treatment,' he added. Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42 and Chairman of Cleveland Clinic Abu Dhabi, said: 'Our partnership with Uzbekistan's Ministry of Health is transformational for Uzbekistan's healthcare ecosystem, for the Uzbek people and for global diversity in genomics research. With the lack of diversity in genomic research, underrepresented populations in the world are having to go without critical benefits ranging from advanced clinical care to early detection of diseases and rational drug design. Building on the success of the Emirati Genome Program, the Uzbek Genome Program is set to contribute to the effort in plugging the gaps in global healthcare and play a significant role in addressing the root causes of genetic diseases, susceptibility to rare diseases, improving patient outcomes and reducing the long-term burden of chronic diseases for the people of Uzbekistan. We are proud to be collaborating with Uzbekistan's Ministry of Health to help create a more sustainable, equitable health future for all.' Dr Fahed Al Marzooqi added: 'By joining forces with Uzbekistan's Ministry of Health, we are partnering in genomics to shift the country's healthcare sector from reaction to prevention and bring tangible health benefits for the Uzbek people. At M42, we have built a powerful genomics engine delivering end-to-end capabilities that is delivering one of the world's largest genomics programs. We have been there and done it and are proud to be working with countries like Uzbekistan on their national genomics programs. We look forward to our ongoing collaboration with Uzbekistan's Ministry of Health on this important initiative to improve the world's health equity.' M42 has built and operated its Omics Center of Excellence into the world's largest facility outside the U.S. with full end-to-end capabilities and the capacity to sample and sequence up to 400,000 genomes annually. About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
